These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. BAY 43-9006 inhibition of oncogenic RET mutants. Carlomagno F; Anaganti S; Guida T; Salvatore G; Troncone G; Wilhelm SM; Santoro M J Natl Cancer Inst; 2006 Mar; 98(5):326-34. PubMed ID: 16507829 [TBL] [Abstract][Full Text] [Related]
25. Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Bocci G; Fioravanti A; La Motta C; Orlandi P; Canu B; Di Desidero T; Mugnaini L; Sartini S; Cosconati S; Frati R; Antonelli A; Berti P; Miccoli P; Da Settimo F; Danesi R Biochem Pharmacol; 2011 Jun; 81(11):1309-16. PubMed ID: 21459081 [TBL] [Abstract][Full Text] [Related]
26. In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Vaccaro A; Chen H; Kunnimalaiyaan M Anticancer Drugs; 2006 Aug; 17(7):849-53. PubMed ID: 16926634 [TBL] [Abstract][Full Text] [Related]
27. Targeting RET for thyroid cancer therapy. Lanzi C; Cassinelli G; Nicolini V; Zunino F Biochem Pharmacol; 2009 Feb; 77(3):297-309. PubMed ID: 19028457 [TBL] [Abstract][Full Text] [Related]
28. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Wang L; Chen W; Xie X; He Y; Bai X Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340 [TBL] [Abstract][Full Text] [Related]
29. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. Kraeber-Bodéré F; Bodet-Milin C; Niaudet C; Saï-Maurel C; Moreau A; Faivre-Chauvet A; Thomare P; Deleris G; Estieu-Gionnet K; Bikfalvi A; Barbet J; Paris F J Nucl Med; 2010 Apr; 51(4):624-31. PubMed ID: 20351352 [TBL] [Abstract][Full Text] [Related]
30. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627 [TBL] [Abstract][Full Text] [Related]
31. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
32. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
33. [Medullary thyroid cancer, a tumour with many appearances]. Verbeek HH; de Groot JW; Plukker JT; Hofstra RW; Brouwers AH; Kerstens MN; Links TP Ned Tijdschr Geneeskd; 2010; 154():A1818. PubMed ID: 20858319 [TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo. Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959 [TBL] [Abstract][Full Text] [Related]
35. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Arthan D; Hong SK; Park JI Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039 [TBL] [Abstract][Full Text] [Related]
36. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898 [TBL] [Abstract][Full Text] [Related]
37. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Ning L; Greenblatt DY; Kunnimalaiyaan M; Chen H Oncologist; 2008 Feb; 13(2):98-104. PubMed ID: 18305053 [TBL] [Abstract][Full Text] [Related]
38. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767 [TBL] [Abstract][Full Text] [Related]
39. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Béhé M; Behr TM Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727 [TBL] [Abstract][Full Text] [Related]
40. The anti-hypertensive drug prazosin induces apoptosis in the medullary thyroid carcinoma cell line TT. Fuchs R; Schwach G; Stracke A; Meier-Allard N; Absenger M; Ingolic E; Haas HS; Pfragner R; Sadjak A Anticancer Res; 2015 Jan; 35(1):31-38. PubMed ID: 25550532 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]